SUZHOU, China – CStone Pharmaceuticals (“CStone”, HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Jiangsu Hengrui Pharmaceuticals (“Hengrui”, SHSE: 600276) today announced a strategic partnership and exclusive licensing agreement on anti-CTLA-4 mAb CS1002 in the Greater China region. This strategic partnership marks...
finance News
NEWPORT BEACH, Calif. – CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, today launched a supplemental newborn screening initiative for Duchenne muscular dystrophy, a rare genetic disorder. The partnership between CureDuchenne and Brigham and Women’s Hospital is the first program to offer supplemental newborn screening...
Toulouse, France – CVasThera, a biopharmaceutical company that specializes in the development of novel therapies for cardiovascular and bowel pathologies, today announces it has secured €1.3 million ($1.6M) in financial backing in its first funding round. These funds will triple the company’s equity and capital. It will enable CVasThera to...
SOUTH SAN FRANCISCO, Calif. and WASHINGTON – Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2021 ALS Roundtables and ALS Focus, a patient and caregiver led survey program to learn about individual...
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2022. Net loss for the fourth quarter was $137.4 million or $1.45 per share and the net loss for the year 2022 was $389.0 million or...
TOKYO & BASKING RIDGE, N.J. & MUNICH & LYON, France – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and LYSA-LYSARC-CALYM today announced that they have entered a strategic research collaboration to study valemetostat (DS-3201), Daiichi Sankyo’s potential first-in-class EZH1/2 dual inhibitor, in B-cell malignancies starting with a phase 2 study...
London, England – There are ~7,000 rare diseases that together affect 300 million people. For the vast majority of these patients there are no approved treatments, representing a huge unmet medical need. Advances in the understanding of the molecular basis of rare diseases, the continued development of therapeutic platforms such...
BOSTON — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “2023 is a very important year for Decibel as we...
BOSTON, Mass. — Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced the filing of multiple patent applications covering novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis (ALS). Composition of matter covered by these applications aims...
TARRYTOWN, N.Y. — Today, Diabetic Tussin, the trusted cough syrup brand for people with diabetes and prediabetes, announces its sugar-free cold and cough solution is back on shelves. This restock brings with it the Better Choices for Life mark from the American Diabetes Association® (ADA). This over-the-counter cold and cough...